Coadministration of Ki16425, an LPA1/3 antagonist, with sunitinib, a tyrosine kinase inhibitor, prolonged the responsiveness of renal cell carcinoma to sunitinib in xenograft models [122]. Here, LPAR1 is linked to hereditary clear cell renal cell carcinoma.